The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeted immunotherapy for HER2-low breast cancer with 17p loss
Li, Y., Sun, Y., Kulke, M., Hechler, T., der Jeught, K. V., Dong, T., He, B., Miller, K. D., Radovich, M., Schneider, B. P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6894 · Cited by 39
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Self-citationMAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationPD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071
Jiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Lim, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.006 · Cited by 1,032
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3185 · Cited by 947
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
The single-cell pathology landscape of breast cancer
Jackson, H. W., Fischer, J. R., Zanotelli, V. R. T., Ali, H. R., Mechera, R., Soysal, S. D., Moch, H., Muenst, S., Varga, Z., Weber, W. P., et al. (2020) · Nature · doi:10.1038/s41586-019-1876-x · Cited by 900
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Wagner, J., Rapsomaniki, M. A., Chevrier, S., Anzeneder, T., Langwieder, C., Dykgers, A., Rees, M., Ramaswamy, A., Muenst, S., Soysal, S. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.005 · Cited by 790
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.801 · Cited by 734
Self-citationGenomic characterization of metastatic breast cancers
Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N., Piscuoglio, S., Carbuccia, N., Soria, J. C., Dien, A. T., Adnani, Y., Kamal, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1056-z · Cited by 713
Nanda, R., Liu, M. C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., Chien, A. J., Forero-Torres, A., Ellis, E., Han, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6650 · Cited by 710
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 695
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Hepatic T cells and liver tolerance
Crispe, I. N. (2003) · Nature Reviews Immunology · doi:10.1038/nri981 · Cited by 661
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Polak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500
Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
Self-citationWiner, E. P., Lipatov, O., Im, S.-A., Goncalves, A., Muñoz-Couselo, E., Lee, K. S., Schmid, P., Tamura, K., Testa, L., Witzel, I., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30754-3 · Cited by 489
Domchek, S. M., Postel-Vinay, S., Im, S.-A., Park, Y. H., Delord, J.-P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30324-7 · Cited by 484
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A., Winer, E. P., Patel, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.355 · Cited by 475
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy127 · Cited by 468
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Gruosso, T., Gigoux, M., Manem, V. S. K., Bertos, N., Zuo, D., Perlitch, I., Saleh, S. M. I., Zhao, H., Souleimanova, M., Johnson, R. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci96313 · Cited by 439
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
(2017) · New England Journal of Medicine · doi:10.1056/nejmx170012 · Cited by 431
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
von Minckwitz, G., Blohmer, J. U., Costa, S. D., Denkert, C., Eidtmann, H., Eiermann, W., Gerber, B., Hanusch, C., Hilfrich, J., Huober, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0940 · Cited by 414
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2098 · Cited by 412
Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 400
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 382
Hu, Z., Li, Z., Ma, Z., & Curtis, C. (2020) · Nature Genetics · doi:10.1038/s41588-020-0628-z · Cited by 374
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Immunological differences between primary and metastatic breast cancer
Szekely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., Silber, A., Park, T., Harigopal, M., Pelekanou, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy399 · Cited by 354
Self-citationZinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer
Yamashita, S., Miyagi, C., Fukada, T., Kagara, N., Che, Y.-S., & Hirano, T. (2004) · Nature · doi:10.1038/nature02545 · Cited by 351
Mutant p53 suppresses innate immune signaling to promote tumorigenesis
Ghosh, M., Saha, S., Bettke, J., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 348
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Targeting the PI3-kinase pathway in triple-negative breast cancer
Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 333
Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328
Bardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.002 · Cited by 326
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Diéras, V., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30447-2 · Cited by 311
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
Ali, H. R., Jackson, H. W., Zanotelli, V. R. T., Danenberg, E., Fischer, J. R., Bardwell, H., Provenzano, E., CRUK IMAXT Grand Challenge Team, Ali, H. R., Al Sa’d, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0026-6 · Cited by 306
Emens, L. A., Molinero, L., Loi, S., Rugo, H. S., Schneeweiss, A., Diéras, V., Iwata, H., Barrios, C. H., Nechaeva, M., Nguyen-Duc, A., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab004 · Cited by 304
Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Adams, S., Diamond, J. R., Hamilton, E., Pohlmann, P. R., Tolaney, S. M., Chang, C.-W., Zhang, W., Iizuka, K., Foster, P. G., Molinero, L., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5152 · Cited by 288
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 286
Self-citationBonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 250
Goodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H.-Y., Frampton, G., Lippman, S. M., Connelly, C., Fabrizio, D., Miller, V., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 247
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
Cubas, R., Zhang, S., Li, M., Chen, C., & Yao, Q. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-253 · Cited by 232
Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., Choudhury, A. D., Gydush, G., Reed, S. C., Rhoades, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0033 · Cited by 231
The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer
Taylor, K. M., Morgan, H. E., Smart, K., Zahari, N. M., Pumford, S., Ellis, I. O., Robertson, J. F. R., & Nicholson, R. I. (2007) · Molecular Medicine · doi:10.2119/2007-00040.taylor · Cited by 230
Wang, X., Wang, S.-S., Huang, H., Cai, L., Zhao, L., Peng, R.-J., Lin, Y., Tang, J., Zeng, J., Zhang, L.-H., et al. (2021) · JAMA · doi:10.1001/jama.2020.23370 · Cited by 229
Bianchini, G., Qi, Y., Alvarez, R. H., Iwamoto, T., Coutant, C., Ibrahim, N. K., Valero, V., Cristofanilli, M., Green, M. C., Radvanyi, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2419 · Cited by 228
Self-citationKarn, T., Denkert, C., Weber, K. E., Holtrich, U., Hanusch, C., Sinn, B. V., Higgs, B. W., Jank, P., Sinn, H. P., Huober, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.015 · Cited by 224
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review
Kono, M., Fujii, T., Lim, B., Karuturi, M. S., Tripathy, D., & Ueno, N. T. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4975 · Cited by 215
Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0155-3 · Cited by 215
Bareche, Y., Buisseret, L., Gruosso, T., Girard, E., Venet, D., Dupont, F., Desmedt, C., Larsimont, D., Park, M., Rothé, F., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz208 · Cited by 215
Yu, K.-D., Ye, F.-G., He, M., Fan, L., Ma, D., Mo, M., Wu, J., Liu, G.-Y., Di, G.-H., Zeng, X.-H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2965 · Cited by 213
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., Durando, A., Turletti, A., Nisticò, C., Valle, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62048-1 · Cited by 206
Litton, J. K., Scoggins, M. E., Hess, K. R., Adrada, B. E., Murthy, R. K., Damodaran, S., DeSnyder, S. M., Brewster, A. M., Barcenas, C. H., Valero, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01304 · Cited by 195
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Iorgulescu, J. B., Gokhale, P. C., Speranza, M. C., Eschle, B. K., Poitras, M. J., Wilkens, M. K., Soroko, K. M., Chhoeu, C., Knott, A., Gao, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2291 · Cited by 189
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park, Y. H., Lal, S., Lee, J. E., Choi, Y.-L., Wen, J., Ram, S., Ding, Y., Lee, S.-H., Powell, E., Lee, S. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19933-0 · Cited by 186
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
Loi, S., Adams, S., Schmid, P., Cortés, J., Cescon, D. W., Winer, E. P., Toppmeyer, D. L., Rugo, H. S., De Laurentiis, M., Nanda, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.005 · Cited by 181
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
Karn, T., Jiang, T., Hatzis, C., Sänger, N., El‐Balat, A., Rody, A., Holtrich, U., Becker, S., Bianchini, G., & Pusztai, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2140 · Cited by 177
Self-citationQin, G., Wang, X., Ye, S., Li, Y., Chen, M., Wang, S., Qin, T., Zhang, C., Li, Y., Long, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15364-z · Cited by 175
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Cullis, J., Siolas, D., Avanzi, A., Barui, S., Maitra, A., & Bar-Sagi, D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0125 · Cited by 162
Bachelot, T., Filleron, T., Bieche, I., Arnedos, M., Campone, M., Dalenc, F., Coussy, F., Sablin, M.-P., Debled, M., Lefeuvre-Plesse, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01189-2 · Cited by 161
Lluch, A. M., Barrios, C. H., Torrecillas, L., Ruíz‐Borrego, M., Bines, J., Segalla, J. G. M., Zotano, Á. G., García-Sáenz, J. Á., Torres, R., de la Haba-Rodríguez, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00904 · Cited by 160
Lehmann, B. D., Abramson, V. G., Sanders, M. E., Mayer, E. L., Haddad, T. C., Nanda, R., Poznak, C. H. V., Storniolo, A. M., Nangia, J. R., Ericsson, P. I. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2170 · Cited by 160
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C. A., Huober, J., Stefek, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.471 · Cited by 160
New Strategies in Breast Cancer: Immunotherapy
Pusztai, L., Karn, T., Safonov, A. M., Abu-Khalaf, M. M., & Bianchini, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1315 · Cited by 157
Self-citationPandy, J. G. P., Balolong-Garcia, J. C., Cruz-Ordinario, M. V. B., & Que, F. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-6253-5 · Cited by 157
Oliveira, M., Saura, C., Nuciforo, P. G., Calvo, I., Andersen, J., Passos‐Coelho, J. L., Gil, M. G., Bermejo, B., Patt, D. A., Ciruelos, E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz177 · Cited by 156
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
Venturini, M., Mastro, L. D., Aitini, E., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji398 · Cited by 154
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer
Safonov, A. M., Jiang, T., Bianchini, G., Győrffy, B., Karn, T., Hatzis, C., & Pusztai, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3478 · Cited by 153
Self-citationRugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiß, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M. M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab108 · Cited by 153
Zou, Y., Zou, X., Zheng, S., Tang, H., Zhang, L., Liu, P., & Xie, X. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920940928 · Cited by 145
Cardillo, T. M., Sharkey, R. M., Rossi, D. L., Arrojo, R., Mostafa, A. A., & Goldenberg, D. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2401 · Cited by 142
Tung, N., Arun, B., Hacker, M. R., Hofstatter, E. W., Toppmeyer, D., Isakoff, S. J., Borges, V. F., Legare, R. D., Isaacs, C. J., Wolff, A. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03292 · Cited by 142
Sobral‐Leite, M., de Vijver, K. K. V., Michaut, M., van der Linden, R., Hooijer, G. K. J., Horlings, H. M., Severson, T., Mulligan, A. M., Weerasooriya, N., Sanders, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1509820 · Cited by 136
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Antón, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-gs3-04 · Cited by 136
Self-citationSchmid, P., Cortés, J., Dent, R. A., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J. C. S., Denkert, C., Park, Y. H., Hui, R., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.014 · Cited by 134
Rozenblit, M., Huang, R. S. P., Danziger, N. A., Hegde, P. S., Alexander, B. M., Ramkissoon, S. H., Blenman, K., Ross, J. S., Rimm, D. L., & Pusztai, L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001558 · Cited by 132
Zhu, L., Narloch, J. L., Onkar, S., Joy, M., Broadwater, G., Luedke, C., Hall, A. H. S., Kim, R., Pogue–Geile, K. L., Sammons, S. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0755-1 · Cited by 125
Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 118
Hutchinson, K. E., Yost, S. E., Chang, C., Johnson, R. M., Carr, A. R., McAdam, P. R., Halligan, D. L., Chang, C.-C., Schmolze, D. B., Liang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1773 · Cited by 117
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Michmerhuizen, A. R., Spratt, D. E., Pierce, L. J., & Speers, C. W. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00190-9 · Cited by 117
Lin, H., Huang, J., Qiu, J., Zhang, H., Tang, X., Li, H., Wang, C., Wang, Z.-C., Feng, Z., & Zhu, J. W. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.08.004 · Cited by 116
Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.009 · Cited by 116
Schmid, P., Im, S., Armstrong, A. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.1023 · Cited by 114
Fassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 102
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
Kalinsky, K. M., Hong, F., McCourt, C. K., Sachdev, J. C., Mitchell, E. P., Zwiebel, J. A., Doyle, L. A., McShane, L. M., Li, S., Gray, R. J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6741 · Cited by 102
Miles, D. W., Gligorov, J., André, F., Cameron, D., Schneeweiß, A., Barrios, C. H., Xu, B., Wardley, A. M., Kaen, D. L., Andrade, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2243 · Cited by 98
Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvement
Manning, D. L., Robertson, J. F. R., Ellis, I. O., Elston, C. W., McClelland, R. A., Gee, J. M. W., Jones, R. J., Green, C. D., Cannon, P., Blamey, R. W., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90543-6 · Cited by 96
Sinkala, M., Nkhoma, P., Mulder, N., & Martin, D. P. (2021) · Communications Biology · doi:10.1038/s42003-020-01552-6 · Cited by 96
Ogiya, R., Niikura, N., Kumaki, N., Yasojima, H., Iwasa, T., Kanbayashi, C., Oshitanai, R., Tsuneizumi, M., Watanabe, K., Matsui, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22110 · Cited by 94
Brufsky, A., Kim, S. B., Zvirbule, Ž., Eniu, A., Mebis, J., Sohn, J. H., Wongchenko, M., Chohan, S., Amin, R., Yan, Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.065 · Cited by 92
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 88
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
den Brok, W. D., Schrader, K. A., Sun, S. B., Tinker, A. V., Stutheit-Zhao, E. Y., Aparicio, S. A. J. R., & Gelmon, K. A. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00031 · Cited by 86
Sharma, P., Abramson, V. G., O’Dea, A. P., Nye, L. E., Mayer, I. A., Pathak, H. B., Hoffmann, M. S., Stecklein, S. R., Elia, M., Lewis, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4879 · Cited by 86
von Minckwitz, G., Rezai, M., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., Hanusch, C. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt410 · Cited by 75
Lwin, Z., Gomez‐Roca, C., Saâda-Bouzid, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2271 · Cited by 75
Cameron, D., Morden, J. P., Canney, P. A., Velikova, G., Coleman, R. E., Bartlett, J. M. S., Agrawal, R. K., Banerji, J., Bertelli, G., Bloomfield, D. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30404-7 · Cited by 72
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
Schafer, J. M., Lehmann, B. D., Ericsson, P. I. G., Marshall, C. B., Beeler, J. S., Redman, L. N., Jin, H., Sanchez, V. M., Stubbs, M. C., Scherle, P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8275 · Cited by 71
Diamond, J. R., Eckhardt, S. G., Pitts, T. M., van Bokhoven, A., Aisner, D. L., Gustafson, D. L., Capasso, A., Sams, S. B., Kabos, P., Zolman, K. L., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1014-y · Cited by 70
Callari, M., Cappelletti, V., D’Aiuto, F., Musella, V., Lembo, A., Petel, F. X., Karn, T., Iwamoto, T., Provero, P., Daidone, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0757 · Cited by 69
Self-citationLoi, S., Winer, E. P., Lipatov, O. N., Im, S., Gonçalvès, A., Cortés, J., Lee, K. S., Schmid, P., Testa, L., Witzel, I., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.sabcs19-pd5-03 · Cited by 68
Modi, S., Pusztai, L., Forero, A., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd3-14 · Cited by 67
Tung, N., Zakalik, D., Somerfield, M. R., & Panel, F. T. H. B. C. G. E. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01532 · Cited by 63
Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Gordon, M. A., D’Amato, N. C., Gu, H., Babbs, B. L., Wulfkuhle, J. D., Petricoin, E. F., Gallagher, R. I., Dong, T., Torkko, K. C., Liu, B., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0111 · Cited by 60
Korn, E. L., Sachs, M. C., & McShane, L. M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv507 · Cited by 56
Ohno, S., Chow, L. W. C., Sato, N., Masuda, N., Sasano, H., Takahashi, F., Bando, H., Iwata, H., Morimoto, T., Kamigaki, S., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2691-y · Cited by 54
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Prestipino, A., & Zeiser, R. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4810 · Cited by 54
Sharma, P., Barlow, W. E., Godwin, A. K., Parkes, E. E., Knight, L. A., Walker, S. M., Kennedy, R. D., Harkin, D. P., Logan, G. E., Steele, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00693 · Cited by 53
Meiri, E., Garrett-Mayer, E. S., Halabi, S., Mangat, P. K., Shrestha, S., Ahn, E. R., Osayameh, O., Perla, V., & Schilsky, R. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.133 · Cited by 52
Bianchini, G., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Russo, S., Ciruelos, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2241 · Cited by 52
Self-citationO’Shaughnessy, J., Moroose, R., Babu, S., Baramidze, K., Chan, D., Leitner, S. P., Nemsadze, G., Ordentlich, P., Quaranto, C., Meyers, M. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1014 · Cited by 49
Schmid, P., Loirat, D., Savas, P. S., Espinosa, E., Boni, V., Italiano, A., White, S. C., Singel, S. M., Withana, N. P., Mani, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct049 · Cited by 47
Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Blum, J. L., Mina, L. A., Brig, R., Danso, M. A., Yuan, Y., Abbattista, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.505 · Cited by 36
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
Li, Y., Vennapusa, B., Chang, C., Tran, D. D., Nakamura, R., Sumiyoshi, T., Hegde, P. S., & Molinero, L. L. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000857 · Cited by 35
Alva, A. S., Mangat, P. K., Garrett-Mayer, E. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1014 · Cited by 32
Bian, L., Zhang, H., Wang, T., Zhang, S., Song, H., Xu, M., Yao, S., & Jiang, Z. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.08 · Cited by 31
Cited by
Triple negative breast cancer: Pitfalls and progress
Zagami, P., & Carey, L. A. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00468-0 · Cited by 839
Towards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 363
Spatial predictors of immunotherapy response in triple-negative breast cancer
Wang, X. Q., Danenberg, E., Huang, C.-S., Egle, D., Callari, M., Bermejo, B., Dugo, M., Zamagni, C., Thill, M., Anton, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06498-3 · Cited by 356
Self-citationAdvances in immunotherapy for triple-negative breast cancer
Liu, Y., Hu, Y., Xue, J., Li, J., Yi, J., Bu, J., Zhang, Z., Qiu, P., & Gu, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01850-7 · Cited by 337
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Metadata
- Authors
- Bianchini, G., De Angelis, C., Licata, L., & Gianni, L.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-11-09
- Volume
- 19
- Issue
- 2
- Pages
- 91-113
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3213834237
- Cited by
- 1,382
- References
- 203
- FWCI
- 24.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.